NEW DELHI: These state-of-the-art tests to be offered from this month are used for diagnosis of pre-natal and post-natal genetic mutations and disorders, chromosomal abnormalities and cancer conditions, the company stated Tuesday. Reliance Life Sciences recently set up a genetic centre as part of its cell biology group. The tie-up with Mumbai-based Thyrocare will offer Reliance Life Sciences access to its franchisee network in over 400 cities reaching out to 50,000 medical consultants and 12,000 laboratories to procure samples and provide air-cargo logistics for the menu of tests being offered by it. An adjunct to the embryonic stem cells research facility and the assisted reproduction facility, the new centre is involved in providing testing using contemporary techniques such as Karyotyping, Fluorescence In-Situ Hybridisation and Polymerase Chain Reaction (PCR), the company stated. These tests can help in early detection of anomalies like Down's syndrome, Patau syndrome, Edward syndrome and for rapid detection and quantitative analysis in the area of oncology and ß-thalassemia. "Reliance Life Sciences looks forward to working synergistically with Thyrocare in making available contemporary biotechnology-based services to millions of needy patients across India," said Mukesh Ambani, chairman and managing director of Reliance Industries Limited. Reliance Life Sciences will provide testing services and make the reports of the tests available through an integrated web-based reporting system. "Business apart, we are keen to provide solution to those hundreds of thousand pregnant woman who are unaware that there is a possibility that they are carrying genetically abnormal children," said Thyrocare managing director A. Velumani in a statement.
Source: IANS